Oruka Therapeutics CEO Lawrence Klein disposes of $2.09 million in common shares

• Oruka Therapeutics CEO Lawrence Otto Klein exercised an employee warrant for 25,000 shares at $7.80 on Oct. 1, 2026.
• He sold 25,000 shares on Oct. 1, 2026 at weighted-average prices of $83.3979, $84.0256, $84.78.
• Directly held common stock fell to 923,128 shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oruka Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000907654-26-000104), on October 02, 2026, and is solely responsible for the information contained therein.